Australien - engelska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 18.666 mg - capsule, modified release - excipient ingredients: gelatin; sodium polystyrene sulfonate; iron oxide black; lactose monohydrate; brilliant blue fcf; titanium dioxide; magnesium stearate; iron oxide yellow; liquid paraffin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 49.79 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; sunset yellow fcf; erythrosine; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 18.67 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; quinoline yellow; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 37.34 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; iron oxide red; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 49.8 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: magnesium stearate; liquid paraffin; lactose; sodium polystyrene sulfonate; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate; carmoisine - novaphen is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with novaphen can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 49.8 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; lactose; liquid paraffin; magnesium stearate; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate; carmoisine - phenterin is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phenterin can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 37.3 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: lactose; sodium polystyrene sulfonate; liquid paraffin; magnesium stearate; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - novaphen is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with novaphen can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 37.3 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; liquid paraffin; magnesium stearate; lactose; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - phenterin is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phenterin can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 18.7 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: lactose; magnesium stearate; sodium polystyrene sulfonate; liquid paraffin; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - novaphen is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with novaphen can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 18.7 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; lactose; magnesium stearate; liquid paraffin; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - phenterin is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phenterin can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.